Aidixi plus BCG led to excessive early response charges and manageable unwanted effects in sufferers with HER2-expressing non–muscle-invasive bladder most cancers.Aidixi (disitamab vedotin),...
The FDA completed its 30-day assessment of Hepzato with customary care in liver-dominant metastatic breast most cancers.Amongst sufferers with liver-dominant metastatic breast most...
Elements like affected person traits and disease-related options affect surgical restoration in addition to therapy success following remedy with Keytruda (pembrolizumab) and Padcev...
